TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Study of the Time Course of Response to Biphentin® Methylphenidate Hydrochloride ER Capsules Compared to Placebo in Children 6 to 12 Years With Attention Deficit Hyperactivity Disorder in Analog Classroom Setting
Brief Summary: The time course of response following one dose of a new methylphenidate hydrochloride extended release capsule is studied in children 6-12 years in a simulated laboratory classroom setting. Biphentin methylphenidate hydrochloride extended release capsule has been formulated for daily dosing to provide treatment of a child with Attention deficit hyperactivity disorder (ADHD) for the substantial day.


Options:
A: Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate
B: Arm Label: ADHD; Type: N/A; Interventions: N/A
C: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Matching Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: OTHER; Name: Matching Placebo; Assigned to Arm(s): Matching Placebo
D: Arm Label: Open Label Phase Then 2-week Double Blind Phase (Placebo First, Then Methylphenidate HCl ER Capsule); Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsule, Drug: Placebo | Arm Label: Open Label Phase Then 2-week Double Blind Phase (Methylphenidate HCl ER Capsule First, Then Placebo); Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsule, Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride Extended Release Capsule; Assigned to Arm(s): Open Label Phase Then 2-week Double Blind Phase (Methylphenidate HCl ER Capsule First, Then Placebo), Open Label Phase Then 2-week Double Blind Phase (Placebo First, Then Methylphenidate HCl ER Capsule) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Open Label Phase Then 2-week Double Blind Phase (Methylphenidate HCl ER Capsule First, Then Placebo), Open Label Phase Then 2-week Double Blind Phase (Placebo First, Then Methylphenidate HCl ER Capsule)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Multi-centre Randomised Placebo-controlled Study of Azithromycin in the Primary Prevention of Radiologically-defined Bronchiectasis in Infants With Cystic Fibrosis.
Brief Summary: The general aim of this project is to conduct a randomized, double-blind, placebo-controlled clinical trial of azithromycin to determine whether treatment from infancy is safe and will prevent the onset of bronchiectasis. One hundred and thirty infants will be recruited from CF clinics in Australia and New Zealand and treated from 3 months to three years of age. The primary outcome will be the proportion with radiologically-defined bronchiectasis at 3 years of age. Safety and mechanistic evaluations will also be undertaken.


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: azithromycin liquid preparation; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: inert liquid preparation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo control | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): azithromycin liquid preparation | Intervention Type: DRUG; Name: Placebo control; Assigned to Arm(s): inert liquid preparation
C: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin 250 mg tablets | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: azithromycin 250 mg tablets; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): Placebo
D: Arm Label: AZLI 75 mg 3 times a day (TID); Type: EXPERIMENTAL; Interventions: Drug: Aztreonam for Inhalation Solution (AZLI) | Arm Label: TIS 300 mg 2 times a day (BID); Type: ACTIVE_COMPARATOR; Interventions: Drug: Tobramycin Inhalation Solution (TIS) | Intervention Type: DRUG; Name: Aztreonam for Inhalation Solution (AZLI); Assigned to Arm(s): AZLI 75 mg 3 times a day (TID) | Intervention Type: DRUG; Name: Tobramycin Inhalation Solution (TIS); Assigned to Arm(s): TIS 300 mg 2 times a day (BID)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing HIV/AIDS and Drug Abuse Among Heroin Addicts Released From Compulsory Rehabilitation in China
Brief Summary: The purpose of the study is to develop and pilot-test a Recovery Management Intervention (RMI) program for heroin addicts released from compulsory rehabilitation in China.

The project has the following specific aims:

Primary aims:

Aim 1. To engage key stakeholders in the local communities involved in supporting the transition of heroin addicts released from compulsory rehabilitation to the community; Aim 2. To identify potential barriers for participating in MMT in China; Aim 3. To develop and deliver educational/training materials on HIV risks, relapse prevention, and MMT; Aim 4. To adapt and develop the Recovery Management Intervention (RMI) program for heroin addicts released from compulsory rehabilitation in China; Aim 5. To conduct a pilot trial and obtain preliminary outcome data associated with RMI, relative to enhanced standard care.

Secondary aim:

Aim 6. To explore predictors of relapse and HIV/AIDS risk behaviors.

It is hypothesized that the intervention will reduce drug use relapse and the negative consequences associated with relapse, including HIV risk behaviors


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Methadone | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): A, B
B: Arm Label: Extended-Release Naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Intervention Type: DRUG; Name: Extended-Release Naltrexone; Assigned to Arm(s): Extended-Release Naltrexone, Placebo
C: Arm Label: Recovery management intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Recovery management | Intervention Type: BEHAVIORAL; Name: Recovery management; Assigned to Arm(s): Recovery management intervention
D: Arm Label: Parolee Comprehensive Care + Phone Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Parolee Comprehensive Care + Phone Coach | Arm Label: Parolee Brief HBV program + Phone Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Parolee Brief HBV Program + Phone Coach | Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Group | Intervention Type: BEHAVIORAL; Name: Parolee Comprehensive Care + Phone Coach; Assigned to Arm(s): Parolee Comprehensive Care + Phone Coach | Intervention Type: BEHAVIORAL; Name: Parolee Brief HBV Program + Phone Coach; Assigned to Arm(s): Parolee Brief HBV program + Phone Coach | Intervention Type: BEHAVIORAL; Name: Usual Care Group; Assigned to Arm(s): Usual Care Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Behavior and Driving Safety Study II
Brief Summary: The purpose of this study is to determine whether brief motivational interviews reduce problematic drinking behavior among individuals arrested for the first time for driving under the influence of alcohol (DUI).


Options:
A: Arm Label: Brief motivational interview; Type: EXPERIMENTAL; Interventions: Behavioral: Brief motivational interview | Arm Label: No discussion; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief motivational interview; Assigned to Arm(s): Brief motivational interview
B: Arm Label: 1 Brief Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief alcohol intervention | Arm Label: 2) Booster; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief alcohol intervention plus booster | Intervention Type: BEHAVIORAL; Name: Brief alcohol intervention; Assigned to Arm(s): 1 Brief Intervention | Intervention Type: BEHAVIORAL; Name: Brief alcohol intervention plus booster; Assigned to Arm(s): 2) Booster
C: Arm Label: 1 - enhanced MI; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Motivational Interview | Arm Label: 2- standard MI; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Motivational Interview or viewing DVD | Intervention Type: BEHAVIORAL; Name: Enhanced Motivational Interview; Assigned to Arm(s): 1 - enhanced MI | Intervention Type: BEHAVIORAL; Name: Standard Motivational Interview or viewing DVD; Assigned to Arm(s): 2- standard MI
D: Arm Label: Motivational Enhancement Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement Therapy (MET) | Arm Label: Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health education | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Therapy (MET); Assigned to Arm(s): Motivational Enhancement Therapy | Intervention Type: BEHAVIORAL; Name: Health education; Assigned to Arm(s): Health Education

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit
Brief Summary: Intensive care unit (ICU) hospitalization saves lives but often does so at a high personal cost to ICU survivors who frequently experience significant cognitive impairment and an array of physical and functional disabilities that limit their recovery and quality of life. While the problems experienced by these patients are likely amenable to rehabilitation, few ICU survivors receive focused rehabilitation. Recently, early physical rehabilitation in ICU patients has shown to improve the chances a patient will regain their pre-hospital functional status. Early cognitive rehabilitation for these patients has not yet been explored. This pilot study will determine the feasibility of early cognitive rehabilitation in ICU patients. The investigators will perform cognitive and physical rehabilitation, beginning in the earliest phases of critical illness, to determine the effect of these therapies on cognitive and functional outcomes in ICU survivors. The investigators hypothesize that combined cognitive and physical rehabilitation, started in the ICU, will improve recovery of cognitive and physical function as well as improve quality of life of ICU survivors.


Options:
A: Arm Label: Patients (Controls); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Behavioral: Phys & Func Rehab; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral: Physical and functional rehabilitation | Arm Label: Behavioral: Cog/Phys/Func Rehab; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral: Cognitive, physical, & functional rehabilitation | Intervention Type: BEHAVIORAL; Name: Behavioral: Physical and functional rehabilitation; Assigned to Arm(s): Behavioral: Phys & Func Rehab | Intervention Type: BEHAVIORAL; Name: Behavioral: Cognitive, physical, & functional rehabilitation; Assigned to Arm(s): Behavioral: Cog/Phys/Func Rehab
B: Arm Label: intravenous propofol/midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol/midazolam | Arm Label: isoflurane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoflurane | Intervention Type: DRUG; Name: Isoflurane; Assigned to Arm(s): isoflurane | Intervention Type: DRUG; Name: Propofol/midazolam; Assigned to Arm(s): intravenous propofol/midazolam
C: Arm Label: No sedatation intervention; Type: OTHER; Interventions: Procedure: Sedation or no sedation during mechanical ventilation | Intervention Type: PROCEDURE; Name: Sedation or no sedation during mechanical ventilation; Assigned to Arm(s): No sedatation intervention
D: Arm Label: 1. Intermittent sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intermittent sedation | Arm Label: 2. Daily interruption of sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Daily interruption of sedation | Intervention Type: PROCEDURE; Name: Intermittent sedation; Assigned to Arm(s): 1. Intermittent sedation | Intervention Type: PROCEDURE; Name: Daily interruption of sedation; Assigned to Arm(s): 2. Daily interruption of sedation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients
Brief Summary: Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung increases the local concentrations of antibiotic at the site of infection resulting in improved antimicrobial effects compared to systemic administration. Bacterial resistance to current aerosol antibiotic treatments indicate a need for improved therapies to treat CF patients with pulmonary infections caused by multi-drug resistant Pseudomonas aeruginosa and other bacteria. High concentrations of MP-376 delivered directly to the lung are projected to have antimicrobial effects on even the most resistant organisms.


Options:
A: Arm Label: AZLI; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZLI, Drug: Tobramycin inhalation solution | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match AZLI, Drug: Tobramycin inhalation solution | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI | Intervention Type: DRUG; Name: Placebo to match AZLI; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tobramycin inhalation solution; Assigned to Arm(s): AZLI, Placebo
B: Arm Label: Aeroquin; Type: EXPERIMENTAL; Interventions: Drug: MP-376 (Levofloxacin Solution for Inhalation) | Arm Label: TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: TIS (Tobramycin Inhalation Solution) | Intervention Type: DRUG; Name: MP-376 (Levofloxacin Solution for Inhalation); Assigned to Arm(s): Aeroquin | Intervention Type: DRUG; Name: TIS (Tobramycin Inhalation Solution); Assigned to Arm(s): TIS
C: Arm Label: Cohort 1 - 280 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 1 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 - 560 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ARIKACE™; Assigned to Arm(s): Cohort 1 - 280 mg ARIKACE™, Cohort 2 - 560 mg ARIKACE™ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 - Placebo, Cohort 2 - Placebo
D: Arm Label: Placebo three times daily (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times daily (TID) | Arm Label: AZLI 75 mg three times daily (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times daily (TID); Assigned to Arm(s): AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: Placebo three times daily (TID); Assigned to Arm(s): Placebo three times daily (TID)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients
Brief Summary: Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung increases the local concentrations of antibiotic at the site of infection resulting in improved antimicrobial effects compared to systemic administration. Bacterial resistance to current aerosol antibiotic treatments indicate a need for improved therapies to treat CF patients with pulmonary infections caused by multi-drug resistant Pseudomonas aeruginosa and other bacteria. High concentrations of MP-376 delivered directly to the lung are projected to have antimicrobial effects on even the most resistant organisms.


Options:
A: Arm Label: Placebo three times daily (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times daily (TID) | Arm Label: AZLI 75 mg three times daily (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times daily (TID); Assigned to Arm(s): AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: Placebo three times daily (TID); Assigned to Arm(s): Placebo three times daily (TID)
B: Arm Label: Aeroquin; Type: EXPERIMENTAL; Interventions: Drug: MP-376 (Levofloxacin Solution for Inhalation) | Arm Label: TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: TIS (Tobramycin Inhalation Solution) | Intervention Type: DRUG; Name: MP-376 (Levofloxacin Solution for Inhalation); Assigned to Arm(s): Aeroquin | Intervention Type: DRUG; Name: TIS (Tobramycin Inhalation Solution); Assigned to Arm(s): TIS
C: Arm Label: Observational; Type: N/A; Interventions: N/A
D: Arm Label: Tobramycin 300 mg for 28 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Arm Label: Tobramycin 300 mg for 56 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Intervention Type: DRUG; Name: Tobramycin solution for inhalation 300 mg; Assigned to Arm(s): Tobramycin 300 mg for 28 days, Tobramycin 300 mg for 56 days

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients
Brief Summary: Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung increases the local concentrations of antibiotic at the site of infection resulting in improved antimicrobial effects compared to systemic administration. Bacterial resistance to current aerosol antibiotic treatments indicate a need for improved therapies to treat CF patients with pulmonary infections caused by multi-drug resistant Pseudomonas aeruginosa and other bacteria. High concentrations of MP-376 delivered directly to the lung are projected to have antimicrobial effects on even the most resistant organisms.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg BID; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 120 mg QD, MP-376 240 mg BID, MP-376 240 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Bramitob; Type: EXPERIMENTAL; Interventions: Drug: tobramycin / Bramitob | Arm Label: TOBI; Type: ACTIVE_COMPARATOR; Interventions: Drug: tobramycin / TOBI | Intervention Type: DRUG; Name: tobramycin / Bramitob; Assigned to Arm(s): Bramitob | Intervention Type: DRUG; Name: tobramycin / TOBI; Assigned to Arm(s): TOBI
C: Arm Label: Cohort 1 - 280 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 1 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 - 560 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ARIKACE™; Assigned to Arm(s): Cohort 1 - 280 mg ARIKACE™, Cohort 2 - 560 mg ARIKACE™ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 - Placebo, Cohort 2 - Placebo
D: Arm Label: Aeroquin; Type: EXPERIMENTAL; Interventions: Drug: MP-376 (Levofloxacin Solution for Inhalation) | Arm Label: TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: TIS (Tobramycin Inhalation Solution) | Intervention Type: DRUG; Name: MP-376 (Levofloxacin Solution for Inhalation); Assigned to Arm(s): Aeroquin | Intervention Type: DRUG; Name: TIS (Tobramycin Inhalation Solution); Assigned to Arm(s): TIS

Answer: D